YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Intellia Therapeutics, Inc. (NTLA) shares rallied 7.6% in the last trading session to close at $12.6. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to t…
In the latest close session, Adma Biologics (ADMA) was up +1.87% at $10.33. This change outpaced the S&P 500's 0.47% loss on the day. Meanwhile, the Dow experienced a rise of 0.1%, and the technology-dominated Nasdaq saw a decrease of 1.25…
Adma Biologics (ADMA) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this infectious disease drug devel…
Adma Biologics (ADMA) closed at $10.00 in the latest trading session, marking a -1.24% move from the prior day. This change lagged the S&P 500's daily loss of 0.17%. Meanwhile, the Dow lost 0.26%, and the Nasdaq, a tech-heavy index, lost 0…
Recent performance swings in ADMA Biologics (ADMA) have put fresh attention on what investors are paying for its plasma-derived therapies business after a year of sharp declines and a much stronger past 3 months. The recent rebound in ADMA…
Adma Biologics (ADMA) closed the most recent trading day at $9.52, moving -1.86% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 0.03%. Elsewhere, the Dow saw a downswing of 0.31%, while the…
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect…
In the latest close session, Adma Biologics (ADMA) was up +2.01% at $9.13. The stock exceeded the S&P 500, which registered a gain of 0.17% for the day. Meanwhile, the Dow lost 0.18%, and the Nasdaq, a tech-heavy index, added 0.4%. Prior t…
Adma Biologics (ADMA) closed at $9.23 in the latest trading session, marking a -1.7% move from the prior day. This change lagged the S&P 500's daily gain of 0.86%. Meanwhile, the Dow experienced a rise of 0.98%, and the technology-dominate…
In the latest close session, Adma Biologics (ADMA) was down 1.01% at $9.36. The stock fell short of the S&P 500, which registered a loss of 0.59% for the day. Meanwhile, the Dow lost 0.6%, and the Nasdaq, a tech-heavy index, lost 0.65%. Sh…
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect…
A month has gone by since the last earnings report for Adma Biologics (ADMA). Shares have lost about 4.8% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading…
ADMA Biologics ADMA is a U.S.-based commercial-stage biopharmaceutical company focused on developing, manufacturing and marketing specialty biologics for immunodeficient patients and individuals at risk of certain infectious diseases. The…
NEW YORK, Aug. 09, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (th…
Friday, August 7, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Space Exploration Technologies Corp. (SPCX), Arista N…
NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA). Shareholders who purchased shares of ADMA during the class period listed are encouraged to c…
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, inclusive (th…
ADMA Biologics, Inc. ADMA reported second-quarter 2026 earnings of 16 cents per share, which matched the Zacks Consensus Estimate and rose from 14 cents in the year-ago quarter. Revenues grew 2.0% year over year to $124.4 million but misse…
LOS ANGELES, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming August 10, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or o…
This article first appeared on GuruFocus. Total Revenue: $124.4 million in Q2 2026, a 2% increase year-over-year. Ascentiv Revenue: $102.9 million, up 24% year-over-year. Bivigam Revenue: $19.4 million, reflecting sequential improvement fr…
SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Hagens Berman alerts investors in ADMA Biologics, Inc. (NASDAQ: ADMA) that a securities fraud class action lawsuit has been filed. The lawsuit focuses on alleged misrepresentations concernin…
Earnings Call Insights: ADMA Biologics (ADMA) Q2 2026 MANAGEMENT VIEW * Adam Grossman (Co-Founder, President, CEO & Director) framed Q2 as accelerating demand for the company’s higher-margin immunoglobulin product: “ASCENIV demand accelera…
ADMA Biologics, Inc. 2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year 2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year-over-Year BIVIGAM Utilization Stabilized with Sequential Improvement in Demand and Re…
PHILADELPHIA, Aug. 05, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”) on behalf of investors who purchased or…
NEW YORK and NEW ORLEANS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. (“ADMA” or the “Company”) (N…
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at…
Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Melissa Fortunato Encourage Investors Who Suffered Losses In ADMA To Contact Them Directly To Discuss Their Options If you purchased or acquired ADMA Biologics securities b…
SAN FRANCISCO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Hagens Berman alerts investors in ADMA Biologics, Inc. (NASDAQ: ADMA) that a securities fraud class action lawsuit has been filed. The lawsuit focuses on alleged misrepresentations concernin…
NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (th…
NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) and certain…
LOS ANGELES, Aug. 03, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the dea…
ATLANTA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC reminds investors of the deadline to seek to be appointed lead plaintiff in the following class action lawsuits: BitGo Holdings, Inc. (BTGO) The shareholder class action lawsu…
In the latest close session, Adma Biologics (ADMA) was down 2.42% at $8.46. This change lagged the S&P 500's daily gain of 0.7%. Meanwhile, the Dow experienced a rise of 0.53%, and the technology-dominated Nasdaq saw an increase of 1%. Sha…
In the latest close session, Adma Biologics (ADMA) was down 2.42% at $8.46. This change lagged the S&P 500's daily gain of 0.7%. Meanwhile, the Dow experienced a rise of 0.53%, and the technology-dominated Nasdaq saw an increase of 1%. Sha…
NEW YORK, July 31, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a top complex litigation law firm, is investigating ADMA Biologics (NASDAQ: ADMA) (“ADMA Biologics” or the “Company”) for potential violations of the federal securities law…
SAN FRANCISCO, July 30, 2026 (GLOBE NEWSWIRE) -- Hagens Berman alerts investors in ADMA Biologics, Inc. (NASDAQ: ADMA) that a securities fraud class action lawsuit has been filed. The lawsuit focuses on alleged misrepresentations concernin…